Patents by Inventor Shigeru Ushiyama

Shigeru Ushiyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190337962
    Abstract: The present invention provides a compound of general formula (I) (wherein X is as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.
    Type: Application
    Filed: December 27, 2017
    Publication date: November 7, 2019
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Ken-ichi KOMORI, Akishi NINOMIYA, Shigeru USHIYAMA, Masaru SHINOHARA, Koji ITO, Tetsuo KAWAGUCHI, Yasunori TOKUNAGA, Hiroyoshi KAWADA, Haruka YAMADA, Yusuke SHIRAISHI, Masahiro KOJIMA, Masaaki ITO, Tomio KIMURA
  • Publication number: 20190256531
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Application
    Filed: April 3, 2019
    Publication date: August 22, 2019
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Noriaki IWASE, Yasuhiro AGA, Shigeru USHIYAMA, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Satoshi UMEZAKI, Masahiro KOJIMA, Kazuhiro ONUMA, Yusuke SHIRAISHI, Makoto OKUDO, Tomio KIMURA
  • Publication number: 20190152953
    Abstract: The present invention provides a compound of general formula (I) (wherein, R1, X, p and q are as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.
    Type: Application
    Filed: August 5, 2016
    Publication date: May 23, 2019
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Ken-ichi KOMORI, Akishi NINOMIYA, Shigeru USHIYAMA, Masaru SHINOHARA, Koji ITO, Tetsuo KAWAGUCHI, Yasunori TOKUNAGA, Hiroyoshi KAWADA, Haruka YAMADA, Yusuke SHIRAISHI, Masahiro KOJIMA, Masaaki ITO, Tomio KIMURA
  • Patent number: 10273252
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: April 30, 2019
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Noriaki Iwase, Yasuhiro Aga, Shigeru Ushiyama, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Satoshi Umezaki, Masahiro Kojima, Kazuhiro Onuma, Yusuke Shiraishi, Makoto Okudo, Tomio Kimura
  • Publication number: 20180360803
    Abstract: The present invention provides the pharmaceutical use of LPA1 antagonists, for example, ?-halogenated thiophene compounds having a specific structure or pharmacologically acceptable salts thereof, as drugs for the treatment and/or prevention of NASH. A pharmaceutical composition for the treatment and/or prevention of NASH includes, as an active ingredient, an LPA1 antagonist, for example, a compound represented by the general formula (I): wherein R1 is a hydrogen atom or a methoxy group, R2 is a hydrogen atom or a C1-C6 alkyl group, X is a halogen atom, and A is a group selected from the group consisting of groups: , or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: November 18, 2016
    Publication date: December 20, 2018
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Kenji NISHIKAWA, Hirofumi MATSUNAGA, Yuuko SHINOHARA, Eiji OKANARI, Shigeru USHIYAMA, Shinpei NONOUCHI
  • Patent number: 10131679
    Abstract: Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 20, 2018
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Yasuhiro Aga, Shigeru Ushiyama, Noriaki Iwase, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Masayuki Tanaka, Masaaki Matoyama, Satoshi Umezaki, Yusuke Shiraishi, Kazuhiro Onuma, Masahiro Kojima, Hayato Nishiyama, Tomio Kimura
  • Publication number: 20180258062
    Abstract: A novel ?-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; R1 is the same or different, and represents a halogen atom, or a C1-C3 alkyl group; R2 represents a hydrogen atom, or a C1-C6 alkyl group; p represents an integer of 0 to 5; V represents CR3 wherein R3 represents a hydrogen atom, an amino group, a nitro group, or a C1-C3 alkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Noriaki IWASE, Hiroshi NISHIDA, Makoto OKUDO, Masaaki ITO, Shigeyuki KONO, Masaaki MATOYAMA, Shigeru USHIYAMA, Eiji OKANARI, Hirofumi MATSUNAGA, Kenji NISHIKAWA, Tomio KIMURA
  • Patent number: 10023554
    Abstract: The invention provides a novel ?-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament. The salt is represented by the general formula (I): (wherein R is a hydrogen atom or a methoxy group; X is a halogen atom; A is selected from the group consisting of: M is an alkali metal or an alkaline earth metal; and n is 1 when M is an alkali metal and is 2 when M is an alkaline earth metal).
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: July 17, 2018
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Noriaki Iwase, Hiroshi Nishida, Makoto Okudo, Masaaki Ito, Shigeyuki Kono, Masaaki Matoyama, Shigeru Ushiyama, Eiji Okanari, Hirofumi Matsunaga, Kenji Nishikawa, Tomio Kimura
  • Publication number: 20180186818
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Application
    Filed: June 14, 2016
    Publication date: July 5, 2018
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Noriaki IWASE, Yasuhiro AGA, Shigeru USHIYAMA, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Satoshi UMEZAKI, Masahiro KOJIMA, Kazuhiro ONUMA, Yusuke SHIRAISHI, Makoto OKUDO, Tomio KIMURA
  • Patent number: 10000463
    Abstract: A novel ?-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: June 19, 2018
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Noriaki Iwase, Hiroshi Nishida, Makoto Okudo, Masaaki Ito, Shigeyuki Kono, Masaaki Matoyama, Shigeru Ushiyama, Eiji Okanari, Hirofumi Matsunaga, Kenji Nishikawa, Tomio Kimura
  • Publication number: 20170313727
    Abstract: Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 2, 2017
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Yasuhiro AGA, Shigeru USHIYAMA, Noriaki IWASE, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Masayuki TANAKA, Masaaki MATOYAMA, Satoshi UMEZAKI, Yusuke SHIRAISHI, Kazuhiro ONUMA, Masahiro KOJIMA, Hayato NISHIYAMA, Tomio KIMURA
  • Patent number: 9676720
    Abstract: The present invention provides a substituted biaryl compound of general formula (I): wherein, R1, W, R2, and Z are as defined in the claims and the description, or a pharmacologically acceptable salt thereof. The compound according to the present invention has an excellent inhibition effect of pulmonary fibroblast proliferation, and is therefore useful as a therapeutic agent and/or a prophylactic agent for interstitial pneumonia and pulmonary fibrosis.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 13, 2017
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Nobuhiko Shibakawa, Kenji Yoneda, Tetsushi Katsube, Tomoko Kanda, Koji Ito, Kiyoshi Yamamoto, Noriaki Iwase, Shigeru Ushiyama
  • Publication number: 20170158663
    Abstract: The invention provides a novel ?-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament. The salt is represented by the general formula (I): (wherein R is a hydrogen atom or a methoxy group; X is a halogen atom; A is selected from the group consisting of: ;M is an alkali metal or an alkaline earth metal; and n is 1 when M is an alkali metal and is 2 when M is an alkaline earth metal).
    Type: Application
    Filed: June 26, 2015
    Publication date: June 8, 2017
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Noriaki IWASE, Hiroshi NISHIDA, Makoto OKUDO, Masaaki ITO, Shigeyuki KONO, Masaaki MATOYAMA, Shigeru USHIYAMA, Eiji OKANARI, Hirofumi MATSUNAGA, Kenji NISHIKAWA, Tomio KIMURA
  • Publication number: 20160213657
    Abstract: Provided is a pharmaceutical composition containing, as an active ingredient thereof, a substituted biaryl compound represented by general formula (I), wherein, R1, W, R2 and Z are as defined in the claims and description, or a pharmacologically acceptable salt thereof. The pharmaceutical composition of the present invention is useful as a therapeutic drug and/or prophylactic drug for chronic obstructive pulmonary disease due to having an excellent anti-inflammatory effect.
    Type: Application
    Filed: September 2, 2014
    Publication date: July 28, 2016
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Kenji YONEDA, Nobuhiko SHIBAKAWA, Tetsushi KATSUBE, Tomoko KANDA, Koji ITO, Kiyoshi YAMAMOTO, Masaru SHINOHARA, Noriaki IWASE, Shigeru USHIYAMA
  • Publication number: 20160060221
    Abstract: The present invention provides a substituted biaryl compound of general formula (I): wherein, R1, W, R2, and Z are as defined in the claims and the description, or a pharmacologically acceptable salt thereof. The compound according to the present invention has an excellent inhibition effect of pulmonary fibroblast proliferation, and is therefore useful as a therapeutic agent and/or a prophylactic agent for interstitial pneumonia and pulmonary fibrosis.
    Type: Application
    Filed: March 28, 2014
    Publication date: March 3, 2016
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Nobuhiko SHIBAKAWA, Kenji YONEDA, Tetsushi KATSUBE, Tomoko KANDA, Koji ITO, Kiyoshi YAMAMOTO, Noriaki IWASE, Shigeru USHIYAMA
  • Publication number: 20150376160
    Abstract: A novel ?-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; R1 is the same or different, and represents a halogen atom, or a C1-C3 alkyl group; R2 represents a hydrogen atom, or a C1-C6 alkyl group; p represents an integer of 0 to 5; V represents CR3 wherein R3 represents a hydrogen atom, an amino group, a nitro group, or a C1-C3 alkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.
    Type: Application
    Filed: June 26, 2015
    Publication date: December 31, 2015
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Noriaki IWASE, Hiroshi NISHIDA, Makoto OKUDO, Masaaki ITO, Shigeyuki KONO, Masaaki MATOYAMA, Shigeru USHIYAMA, Eiji OKANARI, Hirofumi MATSUNAGA, Kenji NISHIKAWA, Tomio KIMURA
  • Publication number: 20060128756
    Abstract: Compounds having activity against production of an inflammatory cytokine of formula (I)?: A? is pyrrole; R1? is phenyl or naphthyl; R2? is pyridyl or pyrimidinyl; R3? is (IIa)?, (IIb)? or (IIc)?: m? is 1; E? is nitrogen; D? is >C(R5?), R5? is hydrogen, Substituent ?? or Substituent ??; B? is nitrogen-containing 5-membered heterocyclic; R4? is 1 to 3 substituents from Substituent ??, Substituent ?? and Substituent ??; R1? and R3? are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2?; Substituent ?? is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa?Rb?; Ra? and Rb? are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra? and Rb? with the nitrogen atom form a heterocyclyl; Substituent ?? is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent ??is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
    Type: Application
    Filed: January 25, 2006
    Publication date: June 15, 2006
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tomio Kimura, Kazumasa Aoki, Akira Nakao, Shigeru Ushiyama, Takaichi Shimozato, Nobuyuki Ohkawa
  • Publication number: 20050283006
    Abstract: Compounds having activity against production of inflammatory cytokines of formula (I)?: A? is pyrrole; R1? is aryl or heteroaryl; R2? is heteroaryl having at least one nitrogen atom; R3? is (IIa)?, (IIb)? or (IIc)?: m? is 1 or 2; one of D? and E? is nitrogen and the other is >C(R5?)—, R5? is hydrogen, Substituent ?? or Substituent ??; B? is nitrogen-containing 4- to 7-membered heterocyclic; R4? is 1 to 3 substituents from Substituent ??, Substituent ?? and Substituent ??; R1? and R3? are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2?; Substituent ??: hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa?Rb?; Ra? and Rb? are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra? and Rb? with the nitrogen atom form a heterocyclyl; Substituent ??: alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent ??: oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkyl
    Type: Application
    Filed: April 10, 2003
    Publication date: December 22, 2005
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tomio Kimura, Kazumasa Aoki, Akira Nakao, Shigeru Ushiyama, Takaichi Shimozato, Nobuyuki Ohkawa, Takayoshi Nagasaki, Takanori Yamazaki
  • Publication number: 20040054173
    Abstract: Compounds having activity against production of an inflammatory cytokine of formula (I)′: 1
    Type: Application
    Filed: January 30, 2003
    Publication date: March 18, 2004
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tomio Kimura, Kazumasa Aoki, Akira Nakao, Shigeru Ushiyama, Takaichi Shimozato, Nobuyuki Ohkawa, Takayoshi Nagasaki, Takanori Yamazaki
  • Patent number: RE39420
    Abstract: Compounds of formula (I) and (II): [wherein R is hydrogen, halogen or alkyl; R1 is alkyl, amino or substituted amino; R2 is optionally substituted phenyl; R3 is hydrogen, halogen or optionally substituted alkyl; R4 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl] have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: December 5, 2006
    Assignee: Sankyo Company, Limited
    Inventors: Tomio Kimura, Yasuo Noguchi, Akira Nakao, Keisuke Suzuki, Shigeru Ushiyama, Akihiro Kawara, Masaaki Miyamoto